Daily Ards Research Analysis
Three studies shape current ARDS-related practice and precision critical care: a pediatric ARDS analysis shows that routine clinical variables cannot reliably infer transpulmonary pressure without esophageal manometry; a clinical pharmacology review outlines how therapeutic drug monitoring and model-informed precision dosing can optimize antibiotics amid inflammation; and an annual ECLS review clarifies uncertainties around VV-ECMO with prone positioning and emphasizes refined ECMO management.
Summary
Three studies shape current ARDS-related practice and precision critical care: a pediatric ARDS analysis shows that routine clinical variables cannot reliably infer transpulmonary pressure without esophageal manometry; a clinical pharmacology review outlines how therapeutic drug monitoring and model-informed precision dosing can optimize antibiotics amid inflammation; and an annual ECLS review clarifies uncertainties around VV-ECMO with prone positioning and emphasizes refined ECMO management.
Research Themes
- Pediatric ARDS mechanics and ventilator management
- Precision dosing and PK/PD under inflammation in critical illness
- ECLS/ECMO evidence updates and management strategies for ARDS
Selected Articles
1. Differentiating Lung From Chest Wall Mechanics Is Difficult Without Esophageal Manometry in Children With Acute Respiratory Distress Syndrome.
In 207 children with PARDS monitored with esophageal manometry, respiratory system compliance tracked lung rather than chest wall compliance, and clinical variables poorly predicted lung-to-respiratory elastance ratio (EL/ERS) or its day-to-day change. Because low CRS generally implies high EL/ERS, increasing plateau pressure above guideline thresholds without esophageal pressure measurement may be unsafe.
Impact: This study provides physiologic evidence specific to PARDS that challenges permissive elevation of plateau pressure without measuring esophageal pressure, directly informing ventilator safety thresholds.
Clinical Implications: Do not justify exceeding Pplat thresholds based solely on presumed chest wall stiffness in PARDS; consider esophageal manometry to individualize transpulmonary pressure. Recognize that CRS largely reflects lung mechanics, reinforcing lung-protective strategies.
Key Findings
- Median EL/ERS was 0.83 (IQR 0.72–0.87) across 207 children on day 1; CRS correlated strongly with lung compliance (r=0.94) and moderately with chest wall compliance (r=0.53).
- CRS was the only independent predictor of EL/ERS categories: lower CRS associated with high EL/ERS (OR 0.70 per 10 mL/cmH2O/kg decrease; AUC 0.73), higher CRS with low EL/ERS (OR 1.14 per 10 increase; AUC 0.60).
- Day-to-day changes in EL/ERS were not predictable from routine clinical variables.
- Implication: when CRS is impaired, EL/ERS is generally high, cautioning against raising Pplat without esophageal pressure measurement.
Methodological Strengths
- Prospective physiological measurements with esophageal manometry embedded in an RCT monitoring protocol
- Large pediatric cohort (N=207; 750 patient-days) with multivariable and ROC analyses
Limitations
- Secondary analysis from a single quaternary PICU limits generalizability
- Predictive performance was modest (AUC up to 0.73) and daily changes were not predictable
- No direct linkage to clinical outcomes of exceeding Pplat
Future Directions: Develop bedside surrogates or improved access to esophageal manometry; multicenter validation; interventional trials of esophageal pressure–guided ventilation in PARDS.
OBJECTIVES: Pediatric acute respiratory distress syndrome (PARDS) guidelines recommend limiting airway plateau pressure (Pplat) to 28 cm H 2 O, allowing for higher limits when chest wall compliance (C CW ) is poor since less of the pressure is transmitted to lung (transpulmonary pressure). Transpulmonary pressure depends on Pplat and the ratio of lung elastance to respiratory system elastance (E L /E RS ). E L /E RS measurement requires esophageal manometry, although it is not routinely available. We sought to determine if routinely available clinical data could reliably predict E L /E RS or changes in E L /E RS , to understand when Pplat greater than 28 cm H 2 O could be acceptable. DESIGN: Secondary analysis of randomized controlled trial with esophageal manometry monitoring. SETTING: Quaternary PICU. PATIENTS: Mechanically ventilated children with PARDS. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Two hundred seven patients and 750 patient days were included. Using the first day per patient, median E L /E RS was 0.83 (interquartile range, 0.72-0.87), with a weak negative correlation with respiratory system compliance (C RS ) ( r = -0.26; p < 0.001). C RS was strongly correlated with lung compliance (C l ) ( r = 0.94; p < 0.001) and moderately correlated with C CW ( r = 0.53; p < 0.001). Multivariable analysis identified that higher C RS , younger age and peripheral neuromuscular disease were associated with higher C CW , while higher C RS was the only variable independently associated with higher C l (all p < 0.01). When trying to predict high (> 0.9) or low (< 0.7) E L /E RS , C RS was the only variable retaining an independent association: lower C RS (C RS × 10 [mL/cm H 2 O/kg × 1/10]) with high E L /E RS (odds ratio [OR], 0.70; 95% CI, 0.54-0.86; p = 0.002; area under the receiver operating characteristic curve [AUC], 0.73) and higher C RS (C RS × 10 [mL/cm H 2 O/kg × 1/10]) with low E L /E RS (OR, 1.14; 95% CI, 1.02-1.28; p = 0.017; AUC, 0.60). Change in E L /E RS from day to day was not predictable. CONCLUSIONS: In PARDS, C RS is more strongly tied to C l than C CW . While E L /E RS is not easily predictable from clinical variables, when C RS is low, E L /E RS is generally high. Therefore, increasing Pplat above the suggested thresholds when C RS is impaired may be inappropriate without measuring esophageal pressure.
2. Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review.
This narrative review synthesizes evidence that standard antibiotic dosing often fails in the ICU due to inflammation-driven PK/PD variability, highlighting therapeutic drug monitoring and model-informed precision dosing as practical solutions. It cautions that inflammatory biomarkers alone are not yet sufficient to guide dosing and calls for integrating biomarkers into PK/PD models and big-data–enabled decision support.
Impact: It consolidates the conceptual and practical framework for precision antibiotic dosing in critical illness, a high-impact, cross-cutting issue in sepsis and ARDS care.
Clinical Implications: Adopt TDM (e.g., for beta-lactams, aminoglycosides) and Bayesian population PK models to individualize dosing in critically ill patients; avoid relying solely on CRP/procalcitonin to guide dosing until validated. Embed PK/PD targets into stewardship to reduce failure and toxicity.
Key Findings
- Standard dosing risks underexposure or overexposure in critically ill patients due to inflammation-driven PK/PD changes.
- Therapeutic drug monitoring and model-informed precision dosing using population PK can improve PK/PD target attainment.
- Inflammatory biomarkers are promising but currently insufficient as standalone dosing guides; integration into PK/PD models and big-data approaches is recommended.
Methodological Strengths
- Comprehensive interdisciplinary synthesis linking inflammation, PK/PD, TDM, and MIPD
- Actionable recommendations for integrating Bayesian population PK into clinical workflows
Limitations
- Narrative review without PRISMA methodology; potential selection bias
- Limited direct clinical outcome data to quantify benefits of MIPD across antibiotic classes
Future Directions: Prospective trials testing biomarker-integrated MIPD platforms; development of bedside decision support using big data and Bayesian updating; validation across ICU subpopulations (e.g., ARDS, septic shock, renal replacement therapy).
Due to extensive pathophysiological changes in critically ill patients, standard dosing of antibiotics may lead to inadequate drug exposure. This is concerning, as insufficient plasma drug concentrations may lead to treatment failure, whereas excessive drug exposure may increase the risk of toxic adverse events. The role of inflammation as a factor influencing the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics remains largely unknown. PK/PD target attainment of antibiotics can be improved through therapeutic drug monitoring, i.e., measurement of drug concentrations in the blood with subsequent dosage adjustment to reach a certain target. Besides, population PK models may be used to predict drug exposure and tailor dosing in an individual patient (model-informed precision dosing). Inflammatory biomarkers have been proposed to measure inflammation levels and guide antibiotic treatment. However, their potential to guide antibiotic dosing is unclear. This narrative review describes associations between inflammation and PK/PD of antibiotics in critically ill patients, and the role of biomarkers, therapeutic drug monitoring and model-informed precision dosing in improving antibiotic dosing. A focus of future research should be on the interplay between inflammation and PK/PD of antibiotics by including inflammatory biomarkers in PK/PD models and using big data to predict antibiotic exposure in critically ill patients.
3. [Annual review of clinical research on extracorporeal life support in 2024].
This annual review summarizes 2024 ECLS evidence: VA-ECMO showed no outcome advantage in AMI with cardiogenic shock and increased complications; micro-axial pumps may reduce mortality; VV-ECMO plus prone positioning for severe ARDS remains uncertain; ECPR benefits in OHCA are further supported; and ECCO2R needs more trials. New guidance emphasizes neurologic monitoring and right ventricular injury management during ECMO, alongside refined targets for oxygenation, anticoagulation, transfusion, and weaning.
Impact: By consolidating rapidly evolving ECLS evidence and 2024 guidance, this review clarifies current uncertainties and operational priorities, directly informing ECMO use in severe ARDS.
Clinical Implications: For severe ARDS on VV-ECMO, the benefit of routine prone positioning remains uncertain; prioritize protocolized neurologic monitoring and right ventricular assessment. Optimize oxygenation targets, anticoagulation, transfusion thresholds, and structured weaning to improve outcomes.
Key Findings
- VA-ECMO did not improve short- or long-term outcomes in AMI with cardiogenic shock and increased bleeding/vascular complications.
- Micro-axial flow pumps showed potential mortality benefits.
- VV-ECMO plus prone positioning for severe ARDS remains uncertain; ECPR survival benefit in OHCA further supported; ECCO2R benefits require more evidence.
- 2024 guidance emphasizes neurologic monitoring and RV injury definition/management during VV-ECMO and refined management targets.
Methodological Strengths
- Up-to-date synthesis spanning multiple ECLS modalities and 2024 guidance
- Translates heterogeneous trial data into pragmatic management priorities
Limitations
- Narrative review design without systematic search or bias assessment
- Lack of granular data on study heterogeneity limits quantitative inference
Future Directions: Conduct RCTs on VV-ECMO plus prone positioning; rigorously evaluate ECCO2R; standardize neurologic monitoring and RV management protocols; optimize anticoagulation and weaning strategies.
The important studies in the field of extracorporeal life support (ECLS) in 2024 focused on the application of cardiac support technologies in acute myocardial infarction (AMI) with cardiogenic shock (CS): veno-arterial extracorporeal membrane oxygenation (V-A ECMO) has not shown advantages in either short- or long-term outcomes and may increase the risk of bleeding and vascular complications; in contrast, micro-axial flow pumps demonstrate potential in improving mortality. The effects of veno-venous extracorporeal membrane oxygenation (V-V ECMO) combined with prone positioning on severe acute respiratory distress syndrome (ARDS) remain uncertain. The survival benefit of extracorporeal cardiopulmonary resuscitation (ECPR) in out-of-hospital cardiac arrest (OHCA) patients has been further validated. The potential benefits of extracorporeal carbon dioxide removal (ECCO2R) require further investigation. Additionally, new guidelines released in 2024 focus on Neurological monitoring and management during ECMO, as well as the Definition and management of right ventricular injury during veno-venous ECMO. ECMO management requires more refined strategies, including optimized oxygenation targets, anticoagulation, blood transfusion, and weaning strategies to improve patient outcomes.